Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC1395 | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.000171 | uM | 12000.165 | 0.9479 | 0.8525 | 0.6978 | |
| HCC1395 | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.000853 | uM | 12000.165 | 0.9687 | 0.9108 | 0.6978 | |
| HCC1395 | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.00427 | uM | 12000.165 | 0.9901 | 0.9716 | 0.6978 | |
| HCC1395 | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.0213 | uM | 12000.165 | 0.9556 | 0.8741 | 0.6978 | |
| HCC1395 | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.107 | uM | 12000.165 | 0.9746 | 0.9276 | 0.6978 | |
| HCC1395 | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.533 | uM | 12000.165 | 0.9080 | 0.7417 | 0.6978 | |
| HCC1395 | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 2.67 | uM | 12000.165 | 0.6136 | -0.0067 | 0.6978 | |
| HCC1395 | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 13.3 | uM | 12000.165 | 0.1925 | -0.8113 | 0.6978 | |
| HCC1395 | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 66.7 | uM | 12000.165 | 0.0073 | -0.9983 | 0.6978 | |
| HCC1395 | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.000171 | uM | 12084.158 | 0.9942 | 0.9911 | 1.2976 | |
| HCC1395 | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.000853 | uM | 12084.158 | 0.9613 | 0.9401 | 1.2976 | |
| HCC1395 | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.00427 | uM | 12084.158 | 1.0364 | 1.0558 | 1.2976 | |
| HCC1395 | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.0213 | uM | 12084.158 | 1.0727 | 1.1112 | 1.2976 | |
| HCC1395 | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.107 | uM | 12084.158 | 0.8979 | 0.8407 | 1.2976 | |
| HCC1395 | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.533 | uM | 12084.158 | 0.9065 | 0.8543 | 1.2976 | |
| HCC1395 | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 2.67 | uM | 12084.158 | 0.4893 | 0.1530 | 1.2976 | |
| HCC1395 | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 13.3 | uM | 12084.158 | 0.0606 | -0.7695 | 1.2976 | |
| HCC1395 | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 66.7 | uM | 12084.158 | 0.0017 | -0.9851 | 1.2976 | |
| HCC1419 | HER2amp | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.000171 | uM | 12001.165 | 0.9623 | 0.8621 | 0.5382 | |
| HCC1419 | HER2amp | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.000853 | uM | 12001.165 | 0.9540 | 0.8326 | 0.5382 | |
| HCC1419 | HER2amp | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.00427 | uM | 12001.165 | 0.8370 | 0.4369 | 0.5382 | |
| HCC1419 | HER2amp | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.0213 | uM | 12001.165 | 0.6601 | -0.0755 | 0.5382 | |
| HCC1419 | HER2amp | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.107 | uM | 12001.165 | 0.3613 | -0.6983 | 0.5382 | |
| HCC1419 | HER2amp | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.533 | uM | 12001.165 | 0.3288 | -0.7467 | 0.5382 | |
| HCC1419 | HER2amp | Luminal | Afatinib | EGFR/HER2 | ErbB | 2.67 | uM | 12001.165 | 0.1521 | -0.9396 | 0.5382 |